Quantcast
Last updated on April 24, 2014 at 1:21 EDT

Latest Factor XI Stories

2012-10-29 07:25:42

CARLSBAD, Calif., Oct. 29, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 comparator-controlled study evaluating ISIS-FXI(Rx) in patients undergoing knee replacement surgery, also referred to as total knee arthroplasty (TKA). ISIS-FXI(Rx) inhibits the production of Factor XI, a coagulation factor produced in the liver that is involved in the formation of clots. In this study, Isis will evaluate the effectiveness of ISIS-FXI(Rx)...